UnknownNot Applicable

Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome

China120 participantsStarted 2015-10

Plain-language summary

Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms. In recent years, there were many studies suggesting that microbiota in the intestine may play an important role in the IBS.What's more, small intestinal bacterial overgrowth (SIBO) may be an important pathogenic factor for IBS and the use of antibiotics may be beneficial. Therefore, the investigators intend to explore the efficacy of rifaximin for IBS-D in Chinese population.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. aged 18-65 yr;
✓. IBS-D fulfiling the ROME III criteria;
✓. had undergone a colonoscopic examination within the previous 2 years;
✓. had received a diagnosis of and had current symptoms of IBS, in particular, symptoms of abdominal pain and discomfort; and did not have adequate relief of global IBS symptoms and of IBS-related bloating at both the time of screening and the time of randomization.

Exclusion criteria

✕. age \<18 years;
✕. use of antimicrobial agents within the previous 3 months;
✕. known hypersensitivity to agents belonging to rifamycin and/or tetracycline families;
✕. pregnancy or breast-feeding;
✕. evidence of major concomitant diseases (including tumours and hepatic and ⁄ or renal insufficiency);
✕. not on antibiotic treatment or probiotics for at least 4 weeks prior to undergoing the LHBT;
✕. fibre supplements or laxatives 1-week prior to the LHBT test date
✕. presence of endoscopic or histological alterations, which might be indicative of other disorders (e.g. celiac disease, inflammatory bowel disease, diverticulosis or diverticulitis) and contribute to IBS symptom generation,

What they're measuring

the proportion of patients who had adequate relief of global IBS symptoms

Timeframe: 12 weeks

Trial details

NCT IDNCT02565654

SponsorFirst Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-10

Contact for this trial

Lishou Xiong, MD PHD

xionglishou@263.net

View on ClinicalTrials.gov More Irritable Bowel Syndrome trials